Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioventus Inc Cl A (NQ: BVS )

13.58 +0.01 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bioventus Inc Cl A

< Previous 1 2 3 Next >
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Second Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bioventus Names Robert Claypoole as President and Chief Executive Officer
Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth 
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Cantor Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Completes Divestiture of its Wound Business
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Divestiture of its Wound Business
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Inc. (NASDAQ:BVS) Long Term Investor Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 04/25/2023 -- An investigation was announced for long-term investors in shares of Bioventus Inc. (NASDAQ:BVS) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
Bioventus Announces CEO Leadership Change
From Bioventus, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.